NASDAQ:MAZE Maze Therapeutics Q3 2026 Earnings Results & Report $34.91 +0.72 (+2.11%) Closing price 04:00 PM EasternExtended Trading$34.88 -0.02 (-0.07%) As of 05:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Maze Therapeutics missed analyst earnings expectations in its Q3 2026 results, released November 9, 2026. The company reported EPS of -$0.79 versus the -$0.78 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2026Report DateNovember 9, 2026TimeAfter Market ClosesConference Call4:00 PM ET Maze Therapeutics EPS ResultsActual EPS-$0.79Consensus EPS -$0.78Beat/MissMissed by -$0.01One Year Ago EPSN/AEPS Beat Rate3 of last 8 quartersMaze Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Maze Therapeutics Q3 2026 Earnings FAQ Did Maze Therapeutics beat earnings estimates for Q3 2026? Maze Therapeutics (NASDAQ:MAZE) reported earnings of -$0.79 per share for Q3 2026, missing the consensus estimate of -$0.78. The report was announced on Monday, November 9, 2026. Maze Therapeutics Earnings HeadlinesMaze Therapeutics Reports Third Quarter 2026 Financial Results and Recent Highlights2 hours ago | globenewswire.comMaze Therapeutics to Participate in Upcoming Investor ConferencesNovember 3, 2026 | globenewswire.comCongress flipped. Trump’s plan just sped up.Democrats took both the House and the Senate. Regardless of how the markets move for the rest of the year, most investors see this as the end of Trump’s crypto agenda. They have it all wrong… The new Congress isn’t sworn in until January 3rd. Until then… Republicans still hold both chambers. And everything Trump has built on crypto runs through the White House and the regulators he appointed. Executive orders. Bank charters. Agency rulings. None of it needs a vote. Which means the next 60 days just became the most important stretch of his presidency for crypto.November 9 at 1:00 AM | Crypto 101 Media (Ad)Maze Therapeutics (NASDAQ:MAZE) Stock: Insider Atul Dandekar Sells 7,500 SharesNovember 1, 2026 | americanbankingnews.comMaze Therapeutics, Inc. (MAZE) Latest Stock News & Headlines - Yahoo FinanceOctober 21, 2026 | finance.yahoo.comMaze Therapeutics adjusts equity via warrant exchangeOctober 16, 2026 | tipranks.comSee More Maze Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Maze Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Maze Therapeutics and other key companies, straight to your email. Email Address About Maze TherapeuticsMaze Therapeutics (NASDAQ:MAZE) is a biopharmaceutical company focused on developing precision medicines for patients with genetically driven diseases. The company uses human genetics and its proprietary Maze Compass platform to identify disease mechanisms, discover drug targets and design therapies intended to address the underlying biology of serious conditions. Maze’s pipeline has included small-molecule programs for rare diseases, including MZE001, an investigational glycogen synthase 1 inhibitor being developed for Pompe disease. The company has also pursued additional programs directed at genetically validated targets in areas such as kidney and metabolic diseases. Its product candidates remain investigational and require clinical testing and regulatory review before they can be marketed. Founded in 2018 and based in South San Francisco, California, Maze Therapeutics conducts its research and development activities primarily in the United States. The company is led by President and Chief Executive Officer Jason Coloma, who has experience in biotechnology company building, drug development and venture investment.View Maze Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Oklo Changes the Narrative: Does a Nuclear Stock Price Explosion Come Next?Wall Street May Be Making a Big Mistake With monday.com StockCloudflare's 20% Sell-Off May Have Created an Opening for InvestorsMarketBeat Week in Review – 11/2 - 11/6IonQ's Record Revenue Includes a Big SkyWater Boost: Does That Change the Story?Atlassian Tanks After Huge Run as Guidance Disappoints, But Strength RemainsThe Ugly Truth Behind SoundHound’s Q3 Results Upcoming Earnings Petroleo Brasileiro S.A.- Petrobras (11/10/2026)Transdigm Group (11/10/2026)Honda Motor (11/11/2026)Franco-Nevada (11/11/2026)Brookfield (11/12/2026)NU (11/12/2026)Applied Materials (11/12/2026)Cisco Systems (11/12/2026)Mizuho Financial Group (11/13/2026)Mitsubishi UFJ Financial Group (11/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
